Peptide Drugs intermediate
Insulin Glargine U300
Concentrated insulin glargine (300 units/mL). Slower absorption from larger subcutaneous depot. T½ ~36 hours. Flatter profile than U-100. Indication: Type 1 and Type 2 diabetes (Toujeo).
By Encyclopeptide Editorial | 1 min read
insulin-glargine-u300 peptide-drug therapeutic
Chemical Identity
| Property | Value |
|---|---|
| Name | Insulin Glargine U300 |
| Description | Concentrated insulin glargine (300 units/mL). Slower absorption from larger subcutaneous depot. T½ ~36 hours. Flatter profile than U-100. Indication: Type 1 and Type 2 diabetes (Toujeo). |
Mechanism of Action
Concentrated insulin glargine (300 units/mL). Slower absorption from larger subcutaneous depot. T½ ~36 hours. Flatter profile than U-100. Indication: Type 1 and Type 2 diabetes (Toujeo).
Clinical Significance
This peptide drug has important therapeutic applications in clinical medicine.
References
- Encyclopeptide Database. “Insulin Glargine U300” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Glargine U300 with interactive quizzes on Wikipept.
Take a Quiz on Wikipept